本文に飛ぶ

年 〜
年

検索結果 1 件

Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance

Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance
デジタル博士論文
岡本, 尚大, 八木, 健太, Imawaka, Sayaka, Takaoka, Mayu, 相澤, 風花, 新村, 貴博, 合田, 光寛, Miyata, Koji, 川田, 敬, (井澤)石澤, 有紀, 坂口, 暁, 石澤, 啓介British Pharmacological Society2024-06-21Pharmacology Research & Perspectives12 4p.e1214-
インターネットで読める全国の図書館
  • 要約等... resistance to BCR-ABL inhibitors makes it diffi......d conventional BCR-ABL inhibitors should be used......mbination with BCR-ABL inhibitors may improve th......f conventional BCR-ABL inhibitors and prevent th......stance between BCR-ABL inhibitors and asciminib may occur, whic...
  • 件名CML chronic myelogenous leukemia Asciminib BCR-ABL inhibitors Drug Resistance

検索結果は以上です。

RSS